Search

Displaying results 5401 - 5410 of 6835 in total
  1. Drug

    Solrikitug

    go.drugbank.com/drugs/DB19301
    Investigational

    Solrikitug is under investigation in clinical trial NCT06496607 (A Study to Evaluate Solriktug in Adult Participants With Asthma).

  2. Drug

    Recanaclotide

    go.drugbank.com/drugs/DB15417
    Investigational

    Recanaclotide is under investigation in clinical trial NCT01712412 (Phase 2a Study of IW-9179 to Treat Functional Dyspepsia).

  3. Drug

    Ethyl butyrate

    go.drugbank.com/drugs/DB15454
    Experimental

    Ethyl butyrate is under investigation in clinical trial NCT03202342 (fMRI of Hypothalamic Responses to Taste, Temperature and Glucose).

  4. Drug

    Buprenorphine hemiadipate

    go.drugbank.com/drugs/DB16117
    Investigational

    Buprenorphine hemiadipate is under investigation in clinical trial NCT01582347 (Transfer of Subjects From Subutex/suboxone to RBP-6300).

  5. Drug

    rhGAD65

    go.drugbank.com/drugs/DB04963
    Investigational

    rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.

  6. Drug

    AAV9/MFSD8

    go.drugbank.com/drugs/DB18616
    Experimental

    AAV9/MFSD8 is a gene therapy developed by Neurogene Inc.

  7. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.

  8. Drug

    Devafidugene civaparvovec

    go.drugbank.com/drugs/DB16790
    Investigational

    Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46716]

  9. Drug

    NGN-401

    go.drugbank.com/drugs/DB18594
    Investigational

    Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.

  10. Drug

    Amilomotide

    go.drugbank.com/drugs/DB05150
    Investigational

    It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.